- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07792408
Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
A Phase 1, Open-label Drug Interaction Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives. This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Medical Information
- Telefonnummer: 617-341-6777
- E-post: medicalinfo@vrtx.com
Studieorter
-
-
-
Montreal, Kanada
- Rekrytering
- Altasciences - Beaumont Clinic Montreal
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
- Body mass index (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m^2), inclusive
- A total body weight of greater than (>) 50 kg
Key Exclusion Criteria:
- History of febrile illness within 5 days before the first dose of study drug
- Pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of study drug
Other protocol defined Inclusion/Exclusion criteria will apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part A: VX-407 With Levonorgestrel/Ethinyl Estradiol (LNG/EE)
Participants will receive a single dose of LNG/EE on Days 1 and 21 in fasted state. Participants will also receive VX-407 every 12 hours (q12h) from Days 8 through 26 in fasted state. |
Tablets for Oral Administration. Combination Tablets for Oral Administration. |
|
Experimentell: Part B (Optional): VX-407 With Norgestimate/Ethinyl Estradiol (NGM/EE)
Participants will receive a single dose of NGM/EE on Days 1 and 23 in fasted state. Participants will also receive VX-407 q12h from Days 10 through 30 in fasted state. |
Tablets for Oral Administration. Combination Tablets for Oral Administration. |
|
Experimentell: Part C (Optional): VX-407 With Norethindrone/Ethinyl Estradiol (NET/EE)
Participants will receive a single dose of NET/EE on Days 1 and 19 in fasted state. Participants will also receive VX-407 q12h from Days 6 through 22 in fasted state. |
Tablets for Oral Administration. Combination Tablets for Oral Administration. |
|
Experimentell: Part D (Optional): VX-407 With Drospirenone/Ethinyl Estradiol (DRSP/EE)
Participants will receive a single dose of DRSP/EE on Days 1 and 21 in fasted state. Participants will also receive VX-407 q12h from Days 8 through 26 in fasted state. |
Tablets for Oral Administration. Combination Tablets for Oral Administration. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Part A: Maximum Observed Plasma Concentration (Cmax) of LNG/EE in the Absence and Presence of VX-407
Tidsram: From Day 1 up to Day 7 and Day 21 up to Day 27
|
From Day 1 up to Day 7 and Day 21 up to Day 27
|
|
Part B (Optional): Maximum Observed Plasma Concentration (Cmax) of norelgestromin (NGMN) and norgestrel (NG) (active metabolites of NGM) and EE in the Absence and Presence of VX-407
Tidsram: From Day 1 up to Day 9 and Day 23 up to Day 31
|
From Day 1 up to Day 9 and Day 23 up to Day 31
|
|
Part C (Optional): Maximum Observed Plasma Concentration (Cmax) of NET and EE in the Absence and Presence of VX-407
Tidsram: From Day 1 up to Day 5 and Day 19 up to Day 23
|
From Day 1 up to Day 5 and Day 19 up to Day 23
|
|
Part D (Optional): Maximum Observed Plasma Concentration (Cmax) of DRSP and EE in the Absence and Presence of VX-407
Tidsram: From Day 1 up to Day 7 and Day 21 up to Day 27
|
From Day 1 up to Day 7 and Day 21 up to Day 27
|
|
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of LNG/EE in the Absence and Presence of VX-407
Tidsram: From Day 1 up to Day 7 and Day 21 up to Day 27
|
From Day 1 up to Day 7 and Day 21 up to Day 27
|
|
Part B (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of norelgestromin (NGMN) and norgestrel (NG) (active metabolites of NGM) and EE in the Absence and Presence of VX-407
Tidsram: From Day 1 up to Day 9 and Day 23 up to Day 31
|
From Day 1 up to Day 9 and Day 23 up to Day 31
|
|
Part C (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of NET and EE in the Absence and Presence of VX-407
Tidsram: From Day 1 up to Day 5 and Day 19 up to Day 23
|
From Day 1 up to Day 5 and Day 19 up to Day 23
|
|
Part D (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of DRSP and EE in the Absence and Presence of VX-407
Tidsram: From Day 1 up to Day 7 and Day 21 up to Day 27
|
From Day 1 up to Day 7 and Day 21 up to Day 27
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: From Day 1 up to Day 36
|
From Day 1 up to Day 36
|
|
Part B (Optional): Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: From Day 1 Up to Day 39
|
From Day 1 Up to Day 39
|
|
Part C (Optional): Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: From Day 1 up to Day 32
|
From Day 1 up to Day 32
|
|
Part D (Optional): Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: From Day 1 up to Day 36
|
From Day 1 up to Day 36
|
|
Part A: Maximum Observed Plasma Concentration (Cmax) of VX-407
Tidsram: Days 9, 15 and 21 up to Day 27
|
Days 9, 15 and 21 up to Day 27
|
|
Part B (Optional): Maximum Observed Plasma Concentration (Cmax) of VX-407
Tidsram: Days 11, 17 and 23 up to Day 31
|
Days 11, 17 and 23 up to Day 31
|
|
Part C (Optional): Maximum Observed Plasma Concentration (Cmax) of VX-407
Tidsram: Days 7, 13 and 19 up to Day 23
|
Days 7, 13 and 19 up to Day 23
|
|
Part D (Optional): Maximum Observed Plasma Concentration (Cmax) of VX-407
Tidsram: Days 9, 15 and 21 up to Day 27
|
Days 9, 15 and 21 up to Day 27
|
|
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407
Tidsram: Days 9, 15 and 21 up to Day 27
|
Days 9, 15 and 21 up to Day 27
|
|
Part B (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407
Tidsram: Days 11, 17 and 23 up to Day 31
|
Days 11, 17 and 23 up to Day 31
|
|
Part C (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407
Tidsram: Days 7, 13 and 19 up to Day 23
|
Days 7, 13 and 19 up to Day 23
|
|
Part D (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407
Tidsram: Days 9, 15 and 21 up to Day 27
|
Days 9, 15 and 21 up to Day 27
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Ciliopatier
- Urogenitala sjukdomar
- Manliga urogenitala sjukdomar
- Njursjukdomar
- Urologiska sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Genetiska sjukdomar, medfödda
- Medfödda abnormiteter
- Avvikelser, flera
- Njursjukdomar, cystisk
- Polycystiska njursjukdomar
- Medfödda, ärftliga och neonatala sjukdomar och abnormiteter
- Polycystisk njure, autosomal dominant
Andra studie-ID-nummer
- VX26-407-014
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .